Abbott India Ltd (ABBOTINDIA)

📊 Quarterly Results (₹ Cr)

Revenue has shown a steady upward trend over the past four quarters, rising from ₹1,738 crore in June 2025 to ₹1,814 crore in June 2026, indicating consistent top-line growth. Operating margins have remained stable around 27%, reflecting pricing power and cost discipline. Net profit and EPS have grown in parallel, with EPS increasing from ₹172.17 in June 2025 to ₹201.66 in June 2026, signaling effective scale and margin retention despite macroeconomic pressures.

🔮 Management Outlook & What's Next

In the Q1FY27 earnings call, management reaffirmed confidence in mid-single-digit growth for the fiscal year, citing strong pipeline execution and rural demand resilience. They projected margin stability, underpinned by favorable raw material costs and efficient inventory management. No major guidance revisions were issued, but management indicated that the new manufacturing facility would enhance capacity and reduce import dependency starting FY28. They also highlighted ongoing cost optimization initiatives as a lever for sustained profitability.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet remains exceptionally strong, with equity of ₹21 crore and reserves of ₹4,753 crore as of March 2026, and zero net borrowings. Total assets grew to ₹6,502 crore, up from ₹5,917 crore a year earlier, reflecting strategic investments in infrastructure and working capital. The company is not leveraging its balance sheet but is actively reinvesting retained earnings into capacity expansion and R&D, maintaining a conservative capital structure with ample liquidity.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 74.99% over the last four quarters, indicating long-term confidence. Institutional ownership has shown a modest uptick, with FII shareholding rising from 0.16% in Q2FY26 to 0.38% in Q1FY27, and DII increasing from 9.11% to 8.78% over the same period. The growing number of public shareholders (78,320 in Q1FY27) suggests improving retail participation. There are no signs of promoter pledging or significant stake sales.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) Margin pressure could emerge if raw material inflation resumes or pricing competition intensifies in key therapeutic segments. 2) The company's heavy reliance on the domestic market makes it vulnerable to regulatory or reimbursement changes in government health schemes. 3) Despite strong cash flows, the recent negative net cash flow from financing activities may signal ongoing capital expenditures or dividend payouts that could constrain flexibility if growth slows.

📋 Recent Filings

• Announcement2026-09-28Abbott India has closed its insider trading window effective October 1, 2026, until two days after reporting Q2 results on September 30, 2026, to comp…
• 🔴 Announcement2026-09-07Abbott India announced the resignation of its Company Secretary and Compliance Officer, Ms. Sangeeta Shetty, effective October 28, 2026, to pursue ext…

🧠 Analyst's Read

Abbott India continues to demonstrate financial resilience and operational excellence, but its premium valuation leaves little room for execution missteps. Investors should monitor rural demand trends, margin sustainability, and the pace of new capacity utilization from recent investments as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.